Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Apr;161(4 Pt 1):1076-80.
doi: 10.1164/ajrccm.161.4.9903087.

Predicting the outcome of therapy for pulmonary tuberculosis

R S Wallis  1 , M D Perkins, M Phillips, M Joloba, A Namale, J L Johnson, C C Whalen, L Teixeira, B Demchuk, R Dietze, R D Mugerwa, K Eisenach, J J Ellner
Affiliations
Clinical Trial

Predicting the outcome of therapy for pulmonary tuberculosis

R S Wallis et al. Am J Respir Crit Care Med. 2000 Apr.

Abstract

Patients vary considerably in their response to treatment of pulmonary tuberculosis. Although several studies have indicated that adverse outcomes are more likely in those patients with delayed sputum sterilization, few tools are available to identify those patients prospectively. In this study, multivariate models were developed to predict the response to therapy in a prospectively recruited cohort of 42 HIV-uninfected subjects with drug-sensitive tuberculosis. The cohort included 2 subjects whose initial response was followed by drug-sensitive relapse. The total duration of culture positivity was best predicted by a model that included sputum M. tuberculosis antigen 85 concentration on Day 14 of therapy, days-to-positive in BACTEC on Day 30, and the baseline radiographic extent of disease (R = 0.63). A model in which quantitative AFB microscopy replaced BACTEC also performed adequately (R = 0.58). Both models predicted delayed clearance of bacilli in both relapses (> 85th percentile of all subjects) using information collected during the first month of therapy. Stratification of patients according to anticipated response to therapy may allow TB treatment to be individualized, potentially offering superior outcomes and greater efficiency in resource utilization, and aiding in the conduct of clinical trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Frequency distributions of day of last rapidly positive culture in BACTEC (indicating mycobacterial growth within 20 d of inoculation (left panel) and that of the day of last positive culture on solid medium (right panel). Subjects from Uganda are indicated in gray; those from Brazil are indicated in black. The two rightmost subjects in both graphs represent relapses.
Figure 2
Figure 2
The relationship between the predicted and observed day of last rapidly positive BACTEC culture, using the multivariate models shown in Table 1. Two relapses are indicated as black squares. The dotted lines indicate equality. The right hand model does not require mycobacterial culture. Predicted values are not shown for those subjects with incomplete data.
See this image and copyright information in PMC

References

    1. Jindani AJ, V, Aber R, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1980;121:939–949. - PubMed
    1. Chan SL, Yew WW, Ma WK, Girling DJ, Aber VR, Felmingham D, Allen BW, Mitchison DA. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis. 1992;73:33–38. - PubMed
    1. Allen BW, Mitchison DA. Counts of viable tubercle bacilli in sputum related to smear and culture gradings. Med Lab Sci. 1992;49:94–98. - PubMed
    1. Sirgel FA, Botha FJ, Parkin DP, Van de Wal BW, Donald PR, Clark PK, Mitchison DA. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother. 1993;32:867–875. - PubMed
    1. Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ML, Van de Wal BW, Maritz JS, Mitchison DA. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med. 1997;156:895–900. - PubMed

Publication types